2023年9月19日 · Several novel therapies targeting the LPA gene transcription rate using small interfering RNAs and gene translation with antisense oligonucleotides are in phase 2 and 3 trials (Table 1).

2023年11月29日 · Lipoprotein apheresis is a recommended treatment option for eligible familial hypercholesterolemia patients with high numbers of both LDL and Lp (a). This procedure involves filtering out both Lp (a) and LDL, temporarily lowering their numbers.

2024年11月18日 · The findings suggest that the therapy could be a promising treatment to help prevent premature heart disease in people with high levels of Lp (a), which is estimated to affect 64 million people in the United States and 1.4 billion people worldwide.

Researchers have found that high levels of lipoprotein (a) can put you at a higher risk of heart and blood vessel disease. Opinions differ on who to test and which method to use, but scientists agree that they need to find a better treatment for high lipoprotein (a) levels.

Anyone who has an elevated Lp (a) should work on lowering their LDL cholesterol as much as possible. People with no history of cardiovascular disease should aim for less than 100 mg/dl. …

2024年5月15日 · Lipoprotein apheresis is the only therapy approved by the Food and Drug Administration (FDA) for treating high Lp (a) levels, and it is only approved for people with FH who have LDL≥100 mg/dL, Lp (a)≥60 mg/dL, and coronary or other artery disease.

2023年2月1日 · About 20% of people have high blood levels of lipoprotein (a)—Lp (a) for short—which can double or triple their risk of a heart attack. With new treatments that can lower Lp (a) on the horizon, cardiologists are now testing more people for this biomarker.

2023年7月12日 · Large amounts of lipoprotein (a) can increase the risk of heart attack and stroke. Here are 5 medications currently in clinical trials to treat high lipoprotein (a) levels.

2023年11月12日 · Research Highlights: In this first trial in people, a single dose of a new therapeutic called lepodisiran reduced the harmful risk factor lipoprotein (a), or Lp (a), by up to 94%, with reductions lasting nearly a year.

2024年1月4日 · Indeed, Lp (a) levels are unaffected by available lipid-lowering therapies or by lifestyle interventions. “Elevated lipoprotein (a) is one of the last untreatable frontiers of cardiovascular risk,” Dr. Nissen notes.